MK0859 Dose-Ranging Study (0859-003)

Phase 2TerminatedNCT00325455

Merck Sharp & Dohme LLC500 enrolled

Overview

To assess the cholesterol changing effects of MK0859 in patients with primary hypercholesterolemia or mixed dyslipidemia.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

500

Conditions

Hypercholesterolemia Mixed Hyperlipemia

Interventions

MK0859DRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Eligible patients will be men and women of non-child bearing potential, 18 through 75 years of age diagnosed with high cholesterol Exclusion Criteria: * Patients with CHD or CHD-equivalent disease (except diabetes) * Diabetics on statins

Outcomes

Primary Outcomes

To assess the cholesterol changing effects of MK0859

Secondary Outcomes

Acceptable safety profile

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.